CA2620281A1 - A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma - Google Patents

A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma Download PDF

Info

Publication number
CA2620281A1
CA2620281A1 CA002620281A CA2620281A CA2620281A1 CA 2620281 A1 CA2620281 A1 CA 2620281A1 CA 002620281 A CA002620281 A CA 002620281A CA 2620281 A CA2620281 A CA 2620281A CA 2620281 A1 CA2620281 A1 CA 2620281A1
Authority
CA
Canada
Prior art keywords
active ingredient
amino
oxy
chlorobenzyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002620281A
Other languages
English (en)
French (fr)
Inventor
Tomas Eriksson
Johan Hansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2620281A1 publication Critical patent/CA2620281A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002620281A 2005-08-26 2006-08-24 A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma Abandoned CA2620281A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0501895-7 2005-08-26
SE0501895 2005-08-26
SE0601221-5 2006-06-01
SE0601221 2006-06-01
PCT/SE2006/000971 WO2007024183A1 (en) 2005-08-26 2006-08-24 A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma

Publications (1)

Publication Number Publication Date
CA2620281A1 true CA2620281A1 (en) 2007-03-01

Family

ID=37771857

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002620281A Abandoned CA2620281A1 (en) 2005-08-26 2006-08-24 A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma

Country Status (12)

Country Link
US (1) US20090298875A1 (enExample)
EP (1) EP1922070A1 (enExample)
JP (1) JP2009506029A (enExample)
KR (1) KR20080038178A (enExample)
AU (1) AU2006282122A1 (enExample)
BR (1) BRPI0615064A2 (enExample)
CA (1) CA2620281A1 (enExample)
IL (1) IL189182A0 (enExample)
MX (1) MX2008002320A (enExample)
NO (1) NO20081483L (enExample)
RU (1) RU2008108176A (enExample)
WO (1) WO2007024183A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
US20110136843A1 (en) * 2007-02-23 2011-06-09 Tomas Eriksson Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
EP2120935A4 (en) * 2007-02-23 2011-06-22 Astrazeneca Ab NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
WO2009074666A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Organic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
EP1294690A2 (en) * 2000-06-21 2003-03-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ATE381537T1 (de) * 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
SE0104251D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
GB0207436D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US20060183731A1 (en) * 2003-07-15 2006-08-17 Min Ge 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity

Also Published As

Publication number Publication date
KR20080038178A (ko) 2008-05-02
JP2009506029A (ja) 2009-02-12
RU2008108176A (ru) 2009-10-10
MX2008002320A (es) 2008-03-14
BRPI0615064A2 (pt) 2011-05-03
US20090298875A1 (en) 2009-12-03
IL189182A0 (en) 2008-08-07
EP1922070A1 (en) 2008-05-21
AU2006282122A1 (en) 2007-03-01
WO2007024183A1 (en) 2007-03-01
NO20081483L (no) 2008-05-16

Similar Documents

Publication Publication Date Title
AU2009202925B2 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma
EP3335707B1 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
JP5208473B2 (ja) アゼラスチンと抗コリン薬を含有する医薬組成物
EP3578169A1 (en) Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US20110124613A1 (en) Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
WO2012168160A1 (en) Dry powder inhaler compositions comprising umeclidinium
US20090298875A1 (en) A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
WO2010097114A1 (en) Novel combination of therapeutic agents
JP5091474B2 (ja) フドステインと抗コリン薬を含有する医薬組成物
HK1116095B (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma.
CN101296698A (zh) 用于治疗呼吸系统疾病，尤其是慢性阻塞性肺病（copd）和哮喘的化合物的组合
JP2009506029A5 (enExample)
CN101296701A (zh) 用于治疗呼吸系统疾病,尤其是慢性阻塞性肺病(copd)和哮喘的化合物的组合
WO2007008157A1 (en) New combination 2
WO2023190976A1 (ja) 呼吸器疾患治療剤
TW202521117A (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
WO2010008341A1 (en) A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
HK1249407B (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
JP2021536467A (ja) 喘息またはパーキンソン病の処置のための方法および組成物

Legal Events

Date Code Title Description
FZDE Discontinued